Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TauroLock and piperacillin-tazobactam for secondary prophylaxis of port-catheter infection
IRCT20180309039013N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of taurolidine and piperacillin + tazobactam in Central venous catheter infection (CLABSI), sponsored by Shiraz University of Medical Sciences. Started Mar 2018; status: completed.
02
Drugs
taurolidinepiperacillin + tazobactam
03
Conditions
Central venous catheter infection (CLABSI)
Beyond the preview
Go deeper on IRCT20180309039013N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180309039013N1.